Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Therapy Using Cellcept and Rebif in RRMS
This study is currently recruiting participants.
Study NCT00618527 Information provided by Ohio State University
First Received: February 6, 2008 Last Updated: February 26, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Sclerosis
Additional conditions recognized in this trial
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Interventions listed in this trial
mycophenolate mofetil (Cellcept)
human interferon beta 1a (Rebif)
Additional drug interventions recognized in this trial
Interferon beta 1a
Interferon Type I, Recombinant
Interferon-beta
Interferons
Mycophenolate mofetil
Mycophenolic Acid
More general drug interventions related to this trial
Adjuvants, Immunologic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Ohio State University
EMD Serono
Pfizer
Back to top of Main Content
